Claims
- 1. A compound of Formula I: wherein:rings “A” and “B”, are unsaturated or partially unsaturated; X1 is selected from CH, or C—Cl; X2 is selected from CR12; X3 is selected from CH; X4 is selected from CH; P1, P2 are both CH; M is N; Q is C1-C3 alkylene or —CH═CH—; R6 is selected from —C(R9)3, —CH(R9)2, or —C3-C8 cycloalkyl; R7 is selected from —SH, OH or OCOR9, wherein R9 is defined below; R8 is —CH2—C4-C6-cycloalkyl; R10 is selected from C1-C3-pyridyl, C3H6OH, —C≡CH, Br, —C≡C—CH2OH, isopropyl, hydrogen, R11 is selected from H, —OH, —O—C3-C8-cycloalkyl, —SH, —Z-pyridyl, —Z-thienyl, and —Z—CH2OH; R12 is selected from —SH, H, halogen or lower alkyl; R9 is lower alkyl; and Z is selected from ethylene, and —C≡C—; and pharmaceutically acceptable salts thereof.
- 2. A compound of claim 1, whereinR6 is selected from —C(CH3)3, —CH(CH2)2; R7 is selected from OH or O—CO—CH3; R10 is selected from —C1-C3-pyridyl, —C3H6OH, —C≡C—, Br, —C≡C—CH2OH, isopropyl, hydrogen, R11 is selected from H and NH2; and X1 is selected from CH or C—Cl.
- 3. A compound of claim 2, wherein R11 is H.
- 4. A compound of claim 3, wherein R10 is selected from isopropyl, propanol, —C═CH, —C═C—CH2OH, C2—H4-pyridyl, Br,
- 5. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutical acceptable carrier.
- 6. A method of effecting selective PDE IV inhibition in mammals requiring the same, which comprises administering an effective amount of a compound of Formula I: wherein:rings “A” and “B”, are unsaturated or partially unsaturated; X1 is selected from CH, or C—Cl; X2 is selected from CR12; X3 is selected from CH; X4 is selected from CH; P1, P2 are both CH; M is N; Q is C1-C3 alkylene or —CH═CH—; R6 is selected from —C(R9)3, —CH(R9)2, or —C3-C8 cycloalkyl; R7 is selected from —SH, OH or OCOR9, wherein R9 is defined below; R8 is selected from —C(R9)3, —CH(R9)2, —C3-C8-cycloalkyl, or —CH2—C4-C6-cycloalkyl; R10 is selected from C1-C3-pyridyl, C3H6OH, —C≡CH, Br, —C≡C—CH2OH, isopropyl, hydrogen, R11 is selected from H, —OH, —O—C3-C8-cycloalkyl, —SH, —Z-pyridyl, —Z-thienyl, and —Z-CH2OH; R12 is selected from —SH, H, halogen or lower alkyl; R9 is lower alkyl; and Z is selected from ethylene, and —C≡C—; and pharmaceutically acceptable salts thereof.
- 7. A compound of Formula I: wherein:rings “A” and “B”, are unsaturated or partially unsaturated; X1 is selected from CH, or C—Cl; X2 is selected from CR12; X3 is selected from CH; X4 is selected from CH; P1, P2 are both CH; M is N; Q is —CH═CH—; R6 is selected from —C(R9)3, —CH(R9)2, or —C3-C8 cycloalkyl; R7 is selected from —SR, OH or OCOR9, wherein R9 is defined below; R8 is selected from —C(R9)3, —CH(R9)2, —C3-C8-cycloalkyl, or —CH2—C4-C6-cycloalkyl; R10 is selected from C1-C3-pyridyl, C3H6OH, —C≡CH, Br, —C≡C—CH2OH, isopropyl, hydrogen, R11 is selected from H, —OH, —O—C3-C8-cycloalkyl, —SH, —Z-pyridyl, —Z-thienyl, and —Z—CH2OH; R12 is selected from —SH, H, halogen or lower alkyl; R9 is lower alkyl; and Z is selected from ethylene, and —C≡C—; and pharmaceutically acceptable salts thereof.
- 8. A pharmaceutical composition comprising a compound of formula I of claim 7 and a pharmaceutically acceptable carrier.
- 9. A method of treating a mammal suffering from a disease state selected from the group consisting of asthma, allergies, inflammation, atopic diseases, rhinitis, and diseased states associated with abnormally high physiological levels of cytokine, comprising administering an effective amount of a compound of Formula I: wherein:rings “A” and “B”, are unsaturated or partially unsaturated; X1 is selected from CH, or C—Cl; X2 is selected from CR12; X3 is selected from CH; X4 is selected from CH; P1, P2 are both CH; M is N; Q is C1-C3 alkylene or —CH═CH—; R6 is selected from —C(R9)3, —CH(R9)2, or —C3-C8 cycloalkyl; R7 is selected from —SH, OH or OCOR9, wherein R9 is defined below; R8 is selected from —C(R9)3, —CH(R9)2, —C3-C8-cycloalkyl, or —CH2—C4-C6-cycloalkyl; R10 is selected from C1-C3-pyridyl, C3H6OH, —C≡CH, Br, —C≡C—CH2OH, isopropyl, hydrogen, R11 is selected from H, —OH, —O—C3-C8-cycloalkyl, —SH, —Z-pyridyl, —Z-thienyl, and —Z—CH2OH; R12 is selected from —SH, H, halogen or lower alkyl; R9 is lower allyl; and Z is selected from ethylene, and —C≡C—; and pharmaceutically acceptable salts thereof.
Parent Case Info
This application is a continuation of U.S. patent application Ser. No. 08/833,893 now U.S. Pat. No. 6,075,016, filed Apr. 10, 1997, the disclosure of which is herein incorporated by reference.
This application claims the benefit of provisional application 60/014917 filed Apr. 10, 1996.
US Referenced Citations (2)
Number |
Name |
Date |
Kind |
5216018 |
Ciganek |
Jun 1993 |
A |
5409929 |
Ciganek |
Apr 1995 |
A |
Provisional Applications (1)
|
Number |
Date |
Country |
|
60/014917 |
Apr 1996 |
US |
Continuations (1)
|
Number |
Date |
Country |
Parent |
08/833893 |
Apr 1997 |
US |
Child |
09/506624 |
|
US |